Short-term use of JAK inhibitors for the treatment of dermatologic conditions does not appear to increase an individual’s risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE), new research suggests.
Findings come from a systematic review of 45 randomized clinical trials including 12,996 patients receiving active JAK-STATi therapy and 4,925 allocated to placebo treatment. Meta-analysis found no significant increase in MACE (I2 = 0.00%; RR, 0.47; 95% CI, 0.28-0.80) or VTE (I2 = 0.00%; RR, 0.46; 95% CI, 0.26-0.80) between placebo and JAK-STATi comparator arms. There was also no significant difference in SAEs (I2 = 12.38%; RR, 0.92; 95% CI, 0.72-1.20) and discontinuations between JAK-STATi and placebo (I2 = 23.55%; RR, 0.94; 95% CI, 0.76-1.19).
The median duration of JAK inhibitor use across the analyzed studies was 16 weeks.
The meta-analysis, published in JAMA Dermatology, included placebo-controlled randomized clinical trials that compared systemic JAKs with placebo in patients with alopecia areata, psoriasis, vitiligo, atopic dermatitis, lichen planus or hidradenitis suppurativa.